AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology.
The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis.
"We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed.
"AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus.
The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce.
To learn more about these solutions or to request a demonstration, please visit www.aixmed.com.
About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit www.aixmed.com.
About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency.
To learn more visit www.corepluspr.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aixmed-and-coreplus-partner-to-demonstrate-a-digital-urine-cytology-workflow-solution-302469884.html
SOURCE AIxMed, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Chronosphere Named a Leader for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Observability Platforms
Chronosphere recognized based on Completeness of Vision and Ability to Execute NEW YORK, July 11, 2025 /PRNewswire/ -- Chronosphere, the observability platform built for control, today announced it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Observability Platforms1. Chronosphere was recognized as a Leader based on Completeness of Vision and Ability to Execute. This marks the second consecutive year Chronosphere has been positioned as a Leader in the Magic Quadrant. "We believe that being recognized as a Leader in the Gartner Magic Quadrant for the second year in a row reinforces the impact we're making on modern engineering teams," said Martin Mao, CEO and Co-Founder of Chronosphere. "As data volumes grow and architectures become more complex, our platform gives organizations the control they need to deliver reliable services, operate efficiently, and scale with confidence—all based on open standards." Chronosphere's product portfolio includes its flagship Observability Platform and its fully integrated Telemetry Pipeline, giving users greater flexibility and vendor neutrality through open standards like OpenTelemetry. With Chronosphere, engineering teams can: Reduce data noise by streamlining data relevant to each role and service. Focus on the data that matters, reducing data volume and associated costs by an average of 84%. Quickly fix issues through guided troubleshooting and correlation across metrics, logs, and traces. Customers report 50% reduced time troubleshooting and 75% fewer incidents with Chronosphere. "Traditional observability solutions require you to keep and pay for all telemetry data, regardless of whether it's useful or not; however, Chronosphere turns this model on its head," continues Mao. "Chronosphere was built to weed out invaluable data, so what's kept in the system, paid for, and used for troubleshooting is the valuable data needed to understand your environment and to remediate immediately. In addition to this recognition in the Gartner Magic Quadrant, Chronosphere was named a Strong Performer in the 2024 Gartner® Peer Insights™ "Voice of the Customer" report for Observability Platforms.2 The Voice of the Customer report, based on aggregated reviews from users and decision-makers, recognized Chronosphere as a Strong Performer, tying for the highest overall rating among all recognized vendors with a 4.7 out of 5 score, based on 70 total reviews as of December 27, 2024. Below are two anonymized reviews of Chronosphere from the company's profile on Gartner Peer Insights™: "Chronosphere: A Comprehensive Solution for Tracking Metrics. Chronosphere provides a wholesome platform for logging and observability. We have used this product to generate dashboards to track various metrics for our services such as latency and QPS. The platform overall is extremely customizable and easy to use. Highly recommend it!" - Software Developer at a $1B+ software company "Chronosphere should be the go-to for Kubernetes monitoring. Chronosphere is a seamless integration with Kubernetes. For Kubernetes heavy products, it's hard to imagine a better fit." - DevOps Engineer at a $10B+ software company To read the full 2025 Gartner® Magic Quadrant™ for Observability Platforms report, download here. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose. Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved About ChronosphereChronosphere is the observability platform built for control in the modern, containerized world. Chronosphere empowers customers to focus on the data and insights that matter by reducing data complexity, optimizing costs, and remediating issues faster. Its Observability Platform reduces data volumes and associated costs by 84% on average while saving developers thousands of hours. Chronosphere's Fluent Bit-based Telemetry Pipeline product optimizes and simplifies observability and security log data. The product transforms logs at the source and routes them to any destination without lock-in. Recognized as a leader by major analyst firms, Chronosphere is trusted by the world's most innovative brands, including Robinhood, DoorDash, and Zillow. Follow and learn more at Follow at LinkedIn and X. 1 Gartner, Magic Quadrant for Observability Platforms, Gregg Siegfried, Padraig Byrne, Andre Bridges, Martin Caren and Matt Crossley, July 7, 2025. 2 Gartner, Voice of the Voice of the Customer for Observability Platforms by Peer Contributors, 24 December 2024. View original content to download multimedia: SOURCE Chronosphere Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Data Acquisition System Quadrant Report 2025
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- 360Quadrants has released its latest Data Acquisition System Startups/SMEs Companies Assessment, 2025, recognizing key players, including both global giants and emerging innovators, for their excellence in market presence, product innovation, and business strategy. The report highlights DataPelago, Logic Fruit Technologies, StrainSense, and Theta Measurement and Control Solutions Pvt Ltd., among the top companies that are actively shaping the future of the Data Acquisition System Startups/SMEs Companies Assessment. The evaluation leverages 360Quadrants' proprietary methodology to map competitive positioning across 7,000+ micro markets within 10+ industries, enabling decision-makers to make strategic, data-backed vendor choices. Company Highlights in the Data Acquisition System Startups/SMEs Companies Assessment: StrainSense was founded in 2002 and is headquartered in Milton Keynes, UK. The company is a specialist provider of sensors, instrumentation, and data acquisition systems. With over two decades of experience, the company delivers tailored sensing solutions—ranging from off-the-shelf modules to bespoke systems—for demanding industries like automotive, aerospace, rail, subsea, and military applications. Theta Measurement and Control Solutions Pvt. Ltd., commonly known as Theta Controls, is an Indian company specializing in advanced test, measurement, and control systems. Based in Pune, Maharashtra, Theta Controls has established itself as a key player in the Data Acquisition Systems (DAQ) and real-time control segments, serving industries such as aerospace, defense, automotive, academic research, and industrial automation. The company has developed a strong portfolio of customized and modular DAQ solutions, leveraging its engineering expertise in electronics, embedded systems, and software development. Theta focuses on delivering reliable, scalable, and high-performance systems tailored to mission-critical applications. To explore the full quadrant report and see how companies are positioned in the Data Acquisition System Startups/SMEs Companies Assessment, 2025,Visit: Evaluation Criteria The vendor evaluation was conducted on over 30 companies, of which the top 4 were categorized and recognized as quadrant leaders. Factors such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Data Acquisition System Startups/Small-Medium Businesses Companies Assessment quadrant. The top criteria for product footprint evaluation included Vertical (Aerospace & Defence, Energy & Power, Automotive & Transportation, Healthcare, Food & Beverages, Wireless Communications & Infrastructure, Civil Structures, Research & Development), Application (Testing and Monitoring), Speed (Low (<100 KS/s) through Ultra High (>100 MS/s), Offering (Hardware, Software and Services). 360 Quadrants Scoring Methodology 360 Quadrants employs a comprehensive and transparent scoring methodology to evaluate companies. It identifies relevant evaluation criteria, collects and validates data from multiple sources, and employs an algorithm that considers parameter weights to generate scores. Normalization ensures fair comparisons, and the aggregated scores categorize solutions into quadrants such as Progressive companies, Responsive companies, Dynamic companies, and Starting blocks. This unbiased approach equips users with accurate information, empowering them to make well-informed decisions and select solutions that best suit their needs and objectives. Download Free Sample @ About 360Quadrants 360Quadrants, a specialized division of MarketsandMarkets™, delivers comprehensive quadrant analyses for various emerging technologies and markets, including start-ups. Our evaluation methodology hinges on two critical parameters: market presence and product footprint. This approach facilitates a graphical representation of competitive positioning across four key categories: leaders, contenders, innovators, and emerging companies. In addition, we meticulously classify start-ups into progressive companies, responsive companies, dynamic companies, and starting blocks. Our expertise equips organizations with insights into market leaders across over 6000 micro markets, enabling a detailed comparison of vendor capabilities and performance. At 360Quadrants, we ensure that each quadrant adheres to the highest standards, empowering our clients to navigate complex market dynamics precisely and confidently. 360Quadrants has also launched quadrants in fields such as – EMC Filtration Startups/SMEs Companies Assessment, 2025, andPressure Washer Startups/SMEs Companies Assessment, 2025. About MarketsandMarkets MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Ms. Sipti Banga,630 Dundee Road, Suite 430Northbrook, IL 60062USA: +1-888-600-6441Email: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a resilient CAGR of 11.7% from 2025 to 2030, culminating in a forecasted valuation of US$15.7 billion by the end of the period. The rising societal emphasis on maintaining a youthful appearance, especially within urban environments and professional contexts, is driving an increasing number of individuals to seek out cosmetic procedures, with botulinum toxins (commonly known as Botox) being among the most popular options. This trend is not restricted to developed nations; in emerging economies, the combination of rising disposable incomes and heightened exposure to Western urban lifestyles is unveiling new demographic groups that are increasingly demanding these cosmetic treatments. Factors contributing to this shift include the influence of social media, where images of youthful faces are amplified, and the cultural valorization of beauty, which places pressure on individuals to look young to compete effectively in professional arenas. Moreover, advancements in the safety and accessibility of botulinum toxin procedures, along with growing awareness of the minimally invasive nature of these treatments, are expected to further fuel market growth. As a result, the botulinum toxins market is projected to experience substantial expansion throughout the forecast period, driven by these changing societal norms and economic factors. Download PDF Brochure: Browse in-depth TOC on "Botulinum Toxins Market" 400 - Tables50 - Figures320 - Pages By product, Botox has a wide range of approved uses and a well-documented safety and efficacy profile. Its consistent diffusion properties lead to desirable results, particularly in cosmetic applications. Additionally, Botox has proven effective in various therapeutic settings, including chronic migraines, dystonia, and spasticity. The use of Botox spans multiple medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its growing demand. Furthermore, Botox is supported by comprehensive training modules and patient support programs. These factors have helped Botox secure a significant share of the botulinum toxins market in 2024. By type, the type A botulinum toxins segment holds the largest market due to its proven clinical efficacy and well-established safety profile, supported by a long history of regulatory approvals. It is preferred over type B botulinum toxins because its effects are more noticeable at lower doses, and it has fewer adverse effects. Type A was the first serotype widely favored, backed by substantial evidence regarding its effectiveness and safety for both therapeutic and aesthetic purposes. Furthermore, type A is approved for a broader range of indications worldwide, including chronic migraine, spasticity, and the reduction of facial wrinkles, which has significantly contributed to its popularity. Additionally, type A botulinum toxins typically have a longer duration of effect, lasting between three and six months. This results in fewer treatment sessions and greater convenience for patients. By application, the botulinum toxins market is divided into two main applications: cosmetic and therapeutic applications. Among these, cosmetic applications are expected to dominate the market, particularly in the area of wrinkle removal. Since 2024, wrinkle removal has become a highly recognized and sought-after use of botulinum toxins, especially among adults looking for non-surgical anti-aging solutions. Clinics report a high volume of patients primarily seeking treatment for forehead lines, crow's feet, and glabellar (frown) lines. This popularity can be attributed to the visible results and relatively quick outcomes associated with the procedure, requiring fewer repeat treatments, which appeals to a wide range of demographics. Additionally, the procedure duration is short, and patients see quick results, making it a preferred choice in non-surgical treatments. By end user, the botulinum toxins market is segmented by end user into dermatology clinics & hospitals, beauty centers, medical spas, other end users, and home care settings. In 2024, dermatology clinics & hospitals held the largest market share. The growing adoption of automated systems in dermatology clinics can be attributed to several key factors that significantly enhance their operational efficiency. As these facilities increasingly integrate advanced technologies, the demand for automation has surged. This trend is not only driven by the desire for improved accuracy in diagnostics and treatments but also by the need for streamlined workflows that can reduce patient wait times and optimize resource allocation. Furthermore, the growing awareness among healthcare professionals about the advantages of automated systems plays a crucial role in their adoption. Clinics are recognizing that automated technologies, such as artificial intelligence-powered diagnostic tools and robotic-assisted treatment devices, can lead to better patient outcomes and greater satisfaction. As dermatology practices continue to evolve, the combination of technological innovation and enhanced patient care will likely contribute to a significant increase in market share for this segment. By geography, the region is distinguished by significant technological innovation and a well-established healthcare infrastructure. It is home to key players involved in the manufacturing and distribution of botulinum toxins. Over the past five years, there have been major developments, expansions, and deals in this area. Favorable macroeconomic indicators, such as supportive funding for startups, manufacturing-friendly regulatory frameworks, and strong healthcare infrastructure, indirectly promote market growth. Request Sample Pages : The key players profiled in the botulinum toxins market are AbbVie, Inc. (US), Ipsen Biopharmaceuticals Inc. (France), Revance Therapeutics, Inc. (US), Evolus, Inc. (US), Hugel, Inc. (South Korea), Medytox, Inc. (South Korea), Daewoong Pharmaceutical Co., Ltd. (South Korea), Merz Pharmaceuticals GmbH (Germany), Supernus Pharmaceuticals, Inc. (US), and Galderma (Switzerland). AbbVie Inc. (US): AbbVie Inc. is a global biopharmaceutical company with six product segments: Immunology, Hematologic Oncology, Aesthetics, Neuroscience, Eye Care, and Other Key Products. Its Aesthetics division provides a wide range of solutions, such as Botox Cosmetic, Juvéderm Collection, and other aesthetic products, including facial injectables, regenerative medicine, body contouring, and skincare items. AbbVie is a leading company in the global medical aesthetics market. Its major strength lies in a strong emphasis on research and innovation, which enables the discovery and development of innovative pharmaceutical products. AbbVie's diverse global presence also contributes to maintaining a robust product pipeline. AbbVie has strategically positioned itself as one of the most well-known biopharmaceutical companies globally, especially in the aesthetics market. The company continues to expand its portfolio with FDA approvals and the launch of new product lines. These include Botox Cosmetic for facial treatments, the Juvéderm Collection for restoring lost volume, and SKINVIVE to smoothen the skin on the cheeks. All of these products are experiencing increased aesthetic demand, which gives AbbVie a competitive advantage in the skincare market. Additionally, AbbVie has further innovated in body contouring with CoolSculpting and has diversified its medical solutions in Neuroscience, Oncology, and Eye Care. Ipsen Biopharmaceuticals Inc. (France) Ipsen Biopharmaceuticals Inc. is a leading specialty biopharmaceutical company, renowned for its botulinum toxin product, Dysport, which is well-established in the therapeutic market. Dysport has received approvals in over 80 countries and is commonly prescribed for various neuromuscular disorders, including upper and lower limb spasticity, cervical dystonia, and pediatric cerebral palsy. While Ipsen has formed strategic partnerships to enhance its presence in the aesthetic segment, its primary strength remains in the medical field. The company is actively engaged in clinical development for new therapeutic indications and has secured a significant share of the global market for therapeutic botulinum toxins, particularly in Europe, Latin America, and parts of Asia. Ipsen's botulinum toxins business offers a stable and growing revenue stream, driven by ongoing geographic expansion and the pursuit of unmet medical needs. Galderma (Switzerland) Galderma excels through its innovative product portfolio and strong regulatory achievements, establishing the company as a leader in dermatology and injectable aesthetics. With robust manufacturing capabilities and a new facility in Singapore, Galderma is well-positioned for sustainable growth. The company maintains a strategic focus on innovation and global expansion, reinforced by strategic alliances that strengthen its dominance in dermatology. Galderma sets itself apart with advanced technologies, including Relfydess, a type A botulinum toxin. Its extensive range of products in injectable aesthetics, dermo-cosmetics, and therapeutic dermatology provides effective solutions for various skin issues. For more information, Inquire Now! Related Reports: Monoclonal Antibody Therapeutics Market GLP-1 Analogues Market Drug Discovery Services Market Pharmaceutical Drug Delivery Market Pharmaceutical Contract Manufacturing Market Get access to the latest updates on Botulinum Toxins Companies and Botulinum Toxins Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
